This article is part of Pulmonology Advisor‘s coverage of the ACAAI 2019 meeting, taking place in Houston, TX. Our staff will report on medical research related to allergies, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2019.
HOUSTON — The majority of patients with cystic fibrosis (CF) have had ≥1 documented antibiotic adverse drug reaction, according to research presented at the 2019 American College of Allergy, Asthma, & Immunology Annual Scientific Meeting, held November 7-11, in Houston, Texas.
Antibiotic use is high among patients with CF as it is an essential element of life-saving care. However, these patients may experience more adverse drug reactions to different types of antibiotics compared with the general population.
Therefore, researchers reviewed medical charts of 115 adult patients with CF to determine types and rates of documented antibiotic adverse reactions. A total of 69.6% of patients had an adverse drug reaction to antibiotics. Reactions potentially mediated by immunoglobulin E (IgE) were most commonly related to penicillins (13.9%), to third- to fifth-generation cephalosporins (8.7%), and to sulfamethoxazole-trimethoprim (7.0%). Adverse drug reactions that would not necessarily prohibit patients from taking the implicated antibiotic (eg, benign non-IgE-mediated or intolerance) were documented in 21.7% of patients.
“Comprehensive evaluation of documented antibiotic [adverse drug reactions] often allows use of implicated antibiotics, either through de-labeling of false IgE-mediated reactions or management of benign non-IgE-mediated reactions and intolerances,” the researchers wrote.
They noted that a clinical program that offers careful evaluation of certain antibiotics would allow patients with CF to receive first-line antibiotic therapy and would close a significant gap in care.
Visit Pulmonology Advisor‘s conference section for continuous coverage from ACAAI 2019.
Anstey K, Kleinhenz M, Otani I. Adverse drug reactions in cystic fibrosis patients: using data to develop an antibiotic evaluation program. Presented at: 2019 American College of Allergy, Asthma, & Immunology Annual Scientific Meeting; November 7-11, 2019; Houston, TX. Abstract A006.
This article originally appeared on Pulmonology Advisor